Recombinant proteins power modern medicine, agriculture, and industry, but making them at scale has always meant expensive, fragile, energy-intensive bioreactors.
Edmonton-based Future Fields is transforming the recombinant protein industry with its innovative, cost-effective, and environmentally sustainable platform. Leveraging patented technology, the company uses fruit flies to produce recombinant proteins for applications in life sciences, healthcare, and therapeutics. To meet growing demand and stringent quality standards, Future Fields is expanding its existing production capacity by more than 200 times with a leading-edge facility. This initiative not only advances biomanufacturing but also cuts greenhouse gas emissions in the sector by an impressive 60-75%.
ERA supported the build-out of Instar, Future Fields’ Edmonton biomanufacturing facility, helping the company scale to meet its commercial commitments.